MedTrace Logo

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-03-30

No results posted yet for this study

Summary

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

XmAb®22841

Monoclonal bispecific antibody

BIOLOGICAL

Pembrolizumab (Keytruda®)

FDA-approved humanized monoclonal antibody

Sponsors & Collaborators

  • ICON Clinical Research

    collaborator INDUSTRY

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Benjamin Thompson, MD, PhD · Xencor, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2023-02-16
Completion
2023-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03849469 on ClinicalTrials.gov